Histone deacetylases in stroke.

Histone deacetylases in stroke.
Chin J Physiol. 2019 May-Jun;62(3):95-107
Authors: Kao MH, Lin TN
Abstract
Stroke is the second leading cause of death and the leading cause of adult disability worldwide. Despite an impressive amount of neuroprotective agents that has been identified in experimental stroke, none of them proved efficient in clinical trials. There is a general consensus that an effective treatment requires the ability to interact with not one, but multiple pathophysiological cascades at different levels that induced by the insult - cocktail therapy. Luckily, recent progress in the field of epigenetics revealed that epigenetic modifications had influence on many known pathways involved in the complex course of ischemic disease development. The fact that epigenetic molecules, by altering transcriptional regulation, may simultaneously act on different levels of ischemic brain injury makes them promising candidates for clinical use. These modifications arise typically owing to deoxyribonucleic acid methylation and histone acetylation. The aim of this review is to give a comprehensive overview of current advances in stroke epigenetics, in particular, the physiological and pathological functions of the 11 classical histone deacetylases.
PMID: 31249263 [PubMed - in process]

Source: The Chinese Journal of Physiology - July 1, 2019 Category: Physiology Tags: Chin J Physiol Source Type: research